New hope for advanced lung cancer patients: experimental combo targets tumors from two angles
NCT ID NCT06924606
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This study tests a new drug called JS207, which targets two proteins (PD-1 and VEGF) that help tumors grow. It is given alone or with another drug (JS004 or docetaxel) to 66 adults with advanced non-small cell lung cancer that got worse after standard chemotherapy and immunotherapy. The goal is to see if these combinations can shrink tumors or control the disease. Participants must have tried platinum-based chemo and a PD-1/PD-L1 inhibitor before joining.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Tumor Hospital of Xinjiang Medical University
RECRUITINGXinjiang, Xinjiang, 830011, China
Contact Email: •••••@•••••
Contact
-
Anyang Tumor Hospital
RECRUITINGAnyang, Henan, 455000, China
Contact Email: •••••@•••••
Contact
-
Army Medical Center, PLA
RECRUITINGChongqing, Chongqing Municipality, 400042, China
Contact
Contact
-
Beijing Chest Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 101100, China
Contact
Contact
-
Harbin Medical University Cancer Hospital
RECRUITINGHeilongjiang, Harbin, 150081, China
Contact
Contact
-
Hunan Cancer Hospital
RECRUITINGHunan, Changsha, 410031, China
Contact
Contact
-
Jilin Cancer Hospital
RECRUITINGJilin, Changchun, 130012, China
Contact
Contact
-
Second Affiliated Hospital, PLA Academy of Military Medical Sciences
RECRUITINGChongqing, Chongqing Municipality, 400037, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, Shanghai Municipality, 200433, China
Contact
Contact
-
Shanghai Pulmonary Hospital
NOT_YET_RECRUITINGShanghai, 200433, China
Contact Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Guangzhou Medical University
RECRUITINGGuangdong, Guangzhou, 510120, China
Contact
Contact
-
The First Affiliated Hospital of Henan University of Science and Technology
RECRUITINGLuoyang, Henan, 471003, China
Contact Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Nanchang University
RECRUITINGJiangxi, Nanchang, 330000, China
Contact
Contact
-
The First Affiliated Hospital of Xinxiang Medical University
RECRUITINGXinxiang, Henan, 453100, China
Contact Email: •••••@•••••
Contact
-
The First People's Hospital of Changde
RECRUITINGChangde, Hunan, 415003, China
Contact Email: •••••@•••••
Contact
-
The Third People's Hospital of Datong
RECRUITINGDatong, Shanxi, 037008, China
Contact Email: •••••@•••••
Contact
-
West China Hospital, Sichuan University
RECRUITINGSichuan, Chengdu, 610044, China
Contact
Contact
-
Yibin Second People's Hospital
RECRUITINGYibin, Sichuan, 644000, China
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.